Tipranavir

Contraindicated

Tipranavir Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details Tipranavir Simvastatin Flolipid Explained An increased risk of myopathy or rhabdomyolysis Details Tipranavir Alfuzosin UroXatral Increased alfuzosin plasma concentrations Details Tipranavir Dihydroergotamine Injection DHE-45® Injection An increased risk of dihydroergotamine toxicity including nausea, vomiting, and vasospastic ischemia Details Tipranavir Dihydroergotamine Nasal Spray Migranal An increased risk of dihydroergotamine toxicity including nausea, vomiting, and vasospastic ischemia Details Tipranavir Flecainide Tambocor® An increased risk of flecainide toxicity including life-threatening cardiac arrhythmias Details Tipranavir Lovastatin Altocor® An increased risk of myopathy or rhabdomyolysis Details Tipranavir Lurasidone Latuda Potential for serious or life-threatening reactions Details Tipranavir Methylergonovine Methergine An increased risk of methylergonovine toxicity including nausea, vomiting, and vasospastic ischemia Details Tipranavir Midazolam Nasal Spray Nayzilam An increased risk of extreme sedation and respiratory depression Details Tipranavir Midazolam Injection Nayzilam An increased risk of extreme sedation and respiratory depression Details

Major

Tipranavir Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine exposure and reduced active metabolite (morphine) exposure Details Tipranavir Ado-Trastuzumab Emtansine Injection KADCYLA Increased exposure of cytotoxic component DM1 (maytansine derivative) and risk of toxicity Details Tipranavir Azathioprine Azasan An increased risk of hepatotoxicity Details Tipranavir Betrixaban Bevyxxa® Decreased betrixaban exposure Details Tipranavir Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Tipranavir Afatinib Gilotrif Decreased afatinib exposure Details Tipranavir Brentuximab Vedotin Injection Adcetris Increased exposure to active entity of brentuximab vedotin Details Tipranavir Brexpiprazole Rexulti Increased brexpiprazole exposure Details Tipranavir Cabazitaxel Injection Jevtana Increased cabazitaxel exposure Details Tipranavir Cabotegravir Apretude Loss of virologic response and possible development of viral resistance Details Tipranavir Cyclophosphamide Cytoxan® Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Tipranavir Cyclophosphamide Injection Cytoxan® Injection Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Tipranavir Dabigatran Pradaxa® Reduced dabigatran exposure, reduced efficacy of dabigatran and an increased risk of thrombosis Details Tipranavir Dabigatran Etexilate Reduced dabigatran exposure, reduced efficacy of dabigatran and an increased risk of thrombosis Details Tipranavir Digoxin Cardoxin® Reduced digoxin exposure Details Tipranavir Dolutegravir Juluca® (as a combination product containing dolutegravir, rilpivirine) Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Tipranavir Doxorubicin Adriamycin Increased or decreased exposure of DOXOrubicin Details Tipranavir Eluxadoline Viberzi Increased eluxadoline exposure Details Tipranavir Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Tipranavir Ifosfamide Injection Ifex Decreased ifosfamide effectiveness Details Tipranavir Ketoconazole Topical Extina® Foam Increased tipranavir exposure and an increased ketoconazole exposure Details Tipranavir Lefamulin Xenleta Reduced lefamulin exposure, reduced efficacy of lefamulin, an increased tipranavir exposure and an increased risk of tipranavir ad... Details Tipranavir Lenacapavir Injection Sunlenca Reduced lenacapavir exposure, reduced efficacy of lenacapavir, increased tipranavir exposure and an increased risk of tipranavir-r... Details Tipranavir Lenacapavir Oral Sunlenca Reduced lenacapavir exposure, reduced efficacy of lenacapavir, increased tipranavir exposure and an increased risk of tipranavir-r... Details Tipranavir Letermovir Injection Prevymis Increased CYP3A substrates exposure, reduced letermovir exposure and reduced efficacy of letermovir Details Tipranavir Levonorgestrel After banger Altered (increased and reduced) levonorgestrel exposure Details Tipranavir Levonorgestrel Intrauterine System Kyleena Altered (increased and reduced) levonorgestrel exposure Details Tipranavir Linagliptin Tradjenta Decreased linagliptin exposure Details Tipranavir Mercaptopurine Purinethol® An increased risk of hepatotoxicity Details